用于增强氧化疗法和化疗的糖基化奎尔丁/西斯丁组合纳米药物
Xu Cheng1, Zhifeng Xie2, Xianming Shi3
1Postdoctoral Research station of Anqing Municipal Hospital, Anqing, Anhui 246003, China; College of Life Sciences, Anqing Normal University, Anqing, Anhui 246133, China.
Colloids and surfaces. B, Biointerfaces
|August 16, 2025
概括
这项研究引入了一种新的糖化驱动的自组装平台,用于增强药物输送. 开发的纳米药物LA-QC@Pt/NPs提高了联合癌症治疗的稳定性,向性和疗效.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 药物自组装在分散性,稳定性和有效性方面面临挑战.
- 单疗法往往显示出不理想的治疗结果.
研究的目的:
- 开发一种共同组装策略,以使用糖化和协调交叉链接来改善药物输送.
- 创建一个稳定的,针对性的纳米药物,用于增强的组合疗法.
主要方法:
- 合成的乳酸 (LA) 修饰的奎尔塞丁 (QC) 衍生物.
- 通过酸和Pt-O协调键形成了LA-QC@Pt/NP.
- 评估了体外稳定性,药物释放,细胞吸收和细胞毒性;评估了体内瘤抑制和毒性.
主要成果:
- LA-QC@Pt/NPs表现出增强的稳定性,在酸性条件下快速释放药物,以及改善的水性分散性.
- 这种纳米药物显著增加了肝细胞癌细胞吸收和细胞毒性.
- 在体内研究表明药物半衰期延长,大量抑制瘤生长,并降低了全身毒性.
结论:
- 甘化驱动的自组装平台为多种药物输送提供了一个有前途的战略.
- LA-QC@Pt/NPs代表了一种有效的组合治疗方法,提高了疗效和安全性.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K


